The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1508-1515

  Holmes, Ann R ^a   Keniya, Mikhail V ^a   Ivnitski Steele, Irena ^b,c   Monk, Brian C ^a   Lamping, Erwin ^a   Sklar, Larry A ^b   Cannon, Richard D ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CACDR2P PROTEIN; CDR1P PROTEIN; CLORGYLINE; DISULFIRAM; DROPERIDOL; EBSELEN; ECONAZOLE; ETHOXYQUIN; FLUCONAZOLE; FLUPENTIXOL; ITRACONAZOLE; MICONAZOLE; PROCHLORPERAZINE MALEATE; RHODAMINE 6G; SULCONAZOLE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CONTROLLED STUDY; FLOW CYTOMETRY; FUNGAL STRAIN; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; YEAST CELL;

ANTIFUNGAL AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CANDIDA ALBICANS; CANDIDA GLABRATA; CLORGYLINE; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; FLOW CYTOMETRY; FLUCONAZOLE; FLUORESCENT DYES; GENE EXPRESSION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROBIAL SENSITIVITY TESTS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; ORGANISMS, GENETICALLY MODIFIED; RHODAMINES; SACCHAROMYCES CEREVISIAE; SMALL MOLECULE LIBRARIES;

EID: 84857173900     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05706-11     Document Type: Article

References (54)

1. Barker KS, Pearson MM, Rogers PD. 2003. Identification of genes differentially expressed in association with reduced azole susceptibility in Saccharomyces cerevisiae. J. Antimicrob. Chemother. 51:1131-1140. (Pubitemid 36622069)
2. Billack B, et al. 2010. Evaluation of the antifungal and plasma membrane H+-ATPase inhibitory action of ebselen and two ebselen analogs in S. cerevisiae cultures. J. Enzyme Inhib. Med. Chem. 25:312-317.
3. Billack B, Santoro M, Lau-Cam C. 2009. Growth inhibitory action of ebselen on fluconazole-resistant Candida albicans: role of the plasma membrane H+-ATPase. Microb. Drug Resist. 15:77-83.
4. Bortolato M, Chen K, Shih JC. 2008. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv. Drug Deliv. Rev. 60:1527-1533.
5. Cannon RD, et al. 2009. Efflux-mediated antifungal drug resistance. Clin. Microbiol. Rev. 22:291-321.
6. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, 3rd ed. CLSI document M27-A3. CLSI, Wayne, PA.
7. Coste A, et al. 2007. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot. Cell 6:1889-1904. (Pubitemid 47585577)
8. Cronin S, Chandrasekar PH. 2010. Safety of triazole antifungal drugs in patients with cancer. J. Antimicrob. Chemother. 65:410-416.
9. Decottignies A, Kolaczkowski M, Balzi E, Goffeau A. 1994. Solubilization and characterization of the overexpressed PDR5 multidrug resistance nucleotide triphosphatase of yeast. J. Biol. Chem. 269:12797-12803. (Pubitemid 24202075)
10. Diwischek F, Morschhauser J, Holzgrabe U. 2009. Cerulenin analogues as inhibitors of efflux pumps in drug-resistant Candida albicans. Arch. Pharm. (Weinheim) 342:150-164.
11. Edwards BS, et al. 2009. High-content screening: flow cytometry analysis. Methods Mol. Biol. 486:151-165.
12. Flamand V, Zhao H, Peehl DM. 2010. Targeting monoamine oxidase A in advanced prostate cancer. J. Cancer Res. Clin. Oncol. 136:1761-1771.
13. Grimsby J, Zentner M, Shih JC. 1996. Identification of a region important for human monoamine oxidase B substrate and inhibitor selectivity. Life Sci. 58:777-787. (Pubitemid 26051846)
14. Holmes AR, et al. 2008. ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. Antimicrob. Agents Chemother. 52:3851-3862.
15. Holmes AR, et al. 2006. Heterozygosity and functional allelic variation in the Candida albicans efflux pump genes CDR1 and CDR2. Mol. Microbiol. 62:170-186. (Pubitemid 44386558)
16. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A. 2000. Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J. Pharmacol. Exp. Ther. 295:1276-1283.
17. Ivnitski-Steele I, et al. 2009. Identification of Nile red as a fluorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p. Anal. Biochem. 394:87-91.
18. Kaludercic N, et al. 2010. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ. Res. 106:193-202.
19. Kanafani ZA, Perfect JR. 2008. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin. Infect. Dis. 46:120-128. (Pubitemid 351263573)
20. Katiyar SK, Edlind TD. 2001. Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei. Med. Mycol. 39:109-116. (Pubitemid 32192925)
21. Khan S, Singhal S, Mathur T, Upadhyay DJ, Rattan A. 2007. Antifungal potential of disulfiram. Nippon Ishinkin Gakkai Zasshi 48:109-113. (Pubitemid 350099307)
22. Kolaczkowski M, Kolaczkowska A, Motohashi N, Michalak K. 2009. Newhigh-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters. Antimicrob. Agents Chemother. 53:1516-1527.
23. Kuckuck FW, Edwards BS, Sklar LA. 2001. High throughput flow cytometry. Cytometry 44:83-90. (Pubitemid 32434006)
24. Lamping E, et al. 2007. Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae. Eukaryot. Cell 6:1150-1165. (Pubitemid 47077167)
25. Lamping E, et al. 2009. Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. Antimicrob. Agents Chemother. 53:354-369.
26. Maher JM, Cheng X, Slitt AL, Dieter MZ, Klaassen CD. 2005. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab. Dispos. 33:956-962. (Pubitemid 41002777)
27. Maki N, et al. 2006. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein. Biochemistry 45:2739-2751.
28. Malloy PJ, Zhao X, Madani ND, Feldman D. 1993. Cloning and expression of the gene from Candida albicans that encodes a high-affinity corticosteroid- binding protein. Proc. Natl. Acad. Sci. U. S. A. 90:1902-1906. (Pubitemid 23069965)
29. Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D. 2000. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob. Agents Chemother. 44:2373-2381. (Pubitemid 30650882)
30. Marr KA, Lyons CN, Ha K, Rustad TR, White TC. 2001. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob. Agents Chemother. 45:52-59. (Pubitemid 32039093)
31. Miceli MH, Diaz JA, Lee SA. 2011. Emerging opportunistic yeast infections. Lancet Infect. Dis. 11:142-151.
32. Monk BC, Goffeau A. 2008. Outwitting multidrug resistance to antifungals. Science 321:367-369. (Pubitemid 352035829)
33. Nakamura K, et al. 2001. Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters. Antimicrob. Agents Chemother. 45:3366-3374. (Pubitemid 33107848)
34. Niimi K, et al. 2004. Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative. Antimicrob. Agents Chemother. 48:1256-1271. (Pubitemid 38405480)
35. Niimi K, et al. 2006. Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob. Agents Chemother. 50:1148-1155.
36. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1. (Pubitemid 36850074)
37. Pajak B, Molnar J, Engi H, Orzechowski A. 2005. Preliminary studies on phenothiazine-mediated reversal of multidrug resistance in mouse lymphoma and COLO 320 cells. In Vivo 19:1101-1104. (Pubitemid 41631518)
38. Park S, Perlin DS. 2005. Establishing surrogate markers for fluconazole resistance in Candida albicans. Microb. Drug Resist. 11:232-238. (Pubitemid 41434167)
39. Ramirez CTA, Andrzejewski B, Sklar LA, Edwards BS. 2003. High-throughput flow cytometry: validation in microvolume bioassays. Cytometry A 53:55-65. (Pubitemid 37521503)
40. Ribeiro MA, Paula CR, John R, Perfect JR, Cox GM. 2005. Phenotypic and genotypic evaluation of fluconazole resistance in vaginal Candida strains isolated from HIV-infected women from Brazil. Med. Mycol. 43:647-650. (Pubitemid 43084522)
41. Ricardo E, et al. 2009. Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes. FEMS Yeast Res. 9:618-625.
42. Sanglard D, Bille J. 2002. Current understanding of the modes of action of and resistance mechanisms to conventional and emerging antifungal agents for treatment of Candida infections, p 349-383. In Calderone R (ed), Candida and candidiasis. ASM Press, Washington, DC.
43. Sanglard D, Ischer F, Bille J. 2001. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob. Agents Chemother. 45:1174-1183. (Pubitemid 32230999)
44. Sanguinetti M, et al. 2005. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother. 49:668-679. (Pubitemid 40175679)
45. Schuetzer-Muehlbauer M, Willinger B, Egner R, Ecker G, Kuchler K. 2003. Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeast. Int. J. Antimicrob. Agents 22:291-300. (Pubitemid 37103216)
46. Spitzer M, et al. 2011. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol. Syst. Biol. 7:499.
47. Tanabe K, et al. 2007. Inhibition of fungal ABC transporters by unnarmicin A and unnarmicin C, novel cyclic peptides from marine bacterium. Biochem. Biophys. Res. Commun. 364:990-995. (Pubitemid 350087898)
48. Tsao S, Rahkhoodaee F, Raymond M. 2009. Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob. Agents Chemother. 53:1344-1352.
49. Vallon O. 2000. New sequence motifs in flavoproteins: evidence for common ancestry and tools to predict structure. Proteins 38:95-114. (Pubitemid 30020606)
50. Vanden Bossche H, Engelen M, Rochette F. 2003. Antifungal agents of use in animal health- chemical, biochemical and pharmacological aspects. J. Vet. Pharmacol. Ther. 26:5-29. (Pubitemid 36308200)
51. White TC. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487. (Pubitemid 27289672)
52. Wirsching S, Moran GP, Sullivan DJ, Coleman DC, Morschhauser J. 2001. MDR1-mediated drug resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 45:3416-3421. (Pubitemid 33107855)
53. Zhang H, et al. 2009. Mechanism of action of tetrandrine, a natural inhibitor of Candida albicans drug efflux pumps. Yakugaku Zasshi 129:623-630.
54. Zhang W, et al. 2002. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab. Dispos. 30:314-318. (Pubitemid 34175023)